2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | NON | AVA | ||
| 3 | NON | NON | ||
| 298 | NON | NON | ||
| 2 | NON | NON | ||
| 1 000 | NON | AVA |
Ylin
18,96VWAP
Alin
17,62VaihtoMäärä
0,9 49 877
VWAP
Ylin
18,96Alin
17,62VaihtoMäärä
0,9 49 877
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·10 t sittenIs there a timeline for getting sales started? 1 week, 1 month, 1 year?
·13 t sittenQuestion for Chat GPt. Could you provide highlights in Danish from Cessatech's Q4 financial report, which was released today Here are the **main points from Cessatech A/S’s financial report for Q4 and the full year 2025 (published today): 📊 Financial key figures 2025 (incl. Q4) Net revenue: 5,718 t.kr. for the full year (compared to 1,989 t.kr. last year – Q4 included) Operating profit (EBIT): -14,967 t.kr. → large negative result, but improved compared to the previous year Net profit/loss for the year: -10,904 t.kr. → continued loss, but reduced loss compared to last year Earnings per share: -0.60 DKK (compared to -0.04 in the quarter) Cash balance at year-end: 8,591 t.kr. Solvency (equity ratio): 91 % – very high solidity No dividend is proposed for 2025. 🚀 Business and development highlights Positive top-line results from the concluding pediatric clinical Study 0202 for CT001 – supports safety and efficacy, and enables initiation of the EU regulatory approval process. Positive Notified Body opinion under EU MDR for CT001 – cleared approval status for the device part. PUMA application (EU's pediatric authorization) for CT001 has been submitted and validated by EMA. Progress in USA: Deepened collaborations and completed technology transfer with STAQ Pharma to support future hospital supply. Strengthened financial position through a directed share issue of approx. DKK 15 mio. Management reinforcement: Martin Juhl joins as CSO. 🧩 Summary / Conclusion Cessatech ended 2025 with increased revenue and reduced loss compared to the previous year. There are significant clinical and regulatory advancements, especially concerning the product CT001 – which is the core product for acute pain management in children. The company is moving closer to the EU approval process and USA activities, but is still at a loss. No dividend is still proposed, and the focus is on strengthening the pipeline and commercialization. In short: The economy is gradually improving, and clinical/regulatory progress is moving Cessatech closer to the potential for commercialization of their main product.
·13 t sittenThe most important thing must be that they, as they have said they can, have gone into economic hibernation. They have therefore only burned through 1,8 mio dkk since the last financial report, which must be said to be extremely impressive. So the cash of 8,5 mio dkk and the loan facility of 10 mio dkk will go a long way :)
·1 päivä sittenThere is an earnings report tomorrow. Does anyone have any insight/input they want to share? Do we believe in a positive? :-)
·20.2.On October 31, 2025, one could read under News that Casatech was approaching the time for the launch of their product in the USA, it has now been almost 4 months since, I know that things take time, but surely there will soon be some kind of announcement about the launch, or could it be that the launch will happen in connection with the event in Denver this March (2026)?
·21.2.I understand that we are waiting for some technical results that need to be in place before the launch in the USA. I imagine they are waiting for stability results that can provide commercially meaningful durability, without actually knowing it. I agree that it would be elegant if the launch was in place in connection with the Denver congress. However, I also don't know if it's Cessatech participating alone or if Ventis also participates, which seems more relevant. I also don't think it's clear if Ventis starts by launching products in their dental division or for pediatric pain treatment? Or both simultaneously?? It sometimes seems a bit like Cessatech is a kind of sub-division of the Secret Service. But I hope they have something cool to tell next time they announce something. And preferably soon.
·20.2.Why are people in such a hurry to sell out🤣
·20.2.There are only a meager 21607 units traded today. Apparently no one is in a hurry. Furthermore, up by 5% right now so not exactly a sign of a sell-off.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenIs there a timeline for getting sales started? 1 week, 1 month, 1 year?
- ·13 t sittenQuestion for Chat GPt. Could you provide highlights in Danish from Cessatech's Q4 financial report, which was released today Here are the **main points from Cessatech A/S’s financial report for Q4 and the full year 2025 (published today): 📊 Financial key figures 2025 (incl. Q4) Net revenue: 5,718 t.kr. for the full year (compared to 1,989 t.kr. last year – Q4 included) Operating profit (EBIT): -14,967 t.kr. → large negative result, but improved compared to the previous year Net profit/loss for the year: -10,904 t.kr. → continued loss, but reduced loss compared to last year Earnings per share: -0.60 DKK (compared to -0.04 in the quarter) Cash balance at year-end: 8,591 t.kr. Solvency (equity ratio): 91 % – very high solidity No dividend is proposed for 2025. 🚀 Business and development highlights Positive top-line results from the concluding pediatric clinical Study 0202 for CT001 – supports safety and efficacy, and enables initiation of the EU regulatory approval process. Positive Notified Body opinion under EU MDR for CT001 – cleared approval status for the device part. PUMA application (EU's pediatric authorization) for CT001 has been submitted and validated by EMA. Progress in USA: Deepened collaborations and completed technology transfer with STAQ Pharma to support future hospital supply. Strengthened financial position through a directed share issue of approx. DKK 15 mio. Management reinforcement: Martin Juhl joins as CSO. 🧩 Summary / Conclusion Cessatech ended 2025 with increased revenue and reduced loss compared to the previous year. There are significant clinical and regulatory advancements, especially concerning the product CT001 – which is the core product for acute pain management in children. The company is moving closer to the EU approval process and USA activities, but is still at a loss. No dividend is still proposed, and the focus is on strengthening the pipeline and commercialization. In short: The economy is gradually improving, and clinical/regulatory progress is moving Cessatech closer to the potential for commercialization of their main product.·13 t sittenThe most important thing must be that they, as they have said they can, have gone into economic hibernation. They have therefore only burned through 1,8 mio dkk since the last financial report, which must be said to be extremely impressive. So the cash of 8,5 mio dkk and the loan facility of 10 mio dkk will go a long way :)
- ·1 päivä sittenThere is an earnings report tomorrow. Does anyone have any insight/input they want to share? Do we believe in a positive? :-)
- ·20.2.On October 31, 2025, one could read under News that Casatech was approaching the time for the launch of their product in the USA, it has now been almost 4 months since, I know that things take time, but surely there will soon be some kind of announcement about the launch, or could it be that the launch will happen in connection with the event in Denver this March (2026)?·21.2.I understand that we are waiting for some technical results that need to be in place before the launch in the USA. I imagine they are waiting for stability results that can provide commercially meaningful durability, without actually knowing it. I agree that it would be elegant if the launch was in place in connection with the Denver congress. However, I also don't know if it's Cessatech participating alone or if Ventis also participates, which seems more relevant. I also don't think it's clear if Ventis starts by launching products in their dental division or for pediatric pain treatment? Or both simultaneously?? It sometimes seems a bit like Cessatech is a kind of sub-division of the Secret Service. But I hope they have something cool to tell next time they announce something. And preferably soon.
- ·20.2.Why are people in such a hurry to sell out🤣·20.2.There are only a meager 21607 units traded today. Apparently no one is in a hurry. Furthermore, up by 5% right now so not exactly a sign of a sell-off.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | NON | AVA | ||
| 3 | NON | NON | ||
| 298 | NON | NON | ||
| 2 | NON | NON | ||
| 1 000 | NON | AVA |
Ylin
18,96VWAP
Alin
17,62VaihtoMäärä
0,9 49 877
VWAP
Ylin
18,96Alin
17,62VaihtoMäärä
0,9 49 877
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 28.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenIs there a timeline for getting sales started? 1 week, 1 month, 1 year?
- ·13 t sittenQuestion for Chat GPt. Could you provide highlights in Danish from Cessatech's Q4 financial report, which was released today Here are the **main points from Cessatech A/S’s financial report for Q4 and the full year 2025 (published today): 📊 Financial key figures 2025 (incl. Q4) Net revenue: 5,718 t.kr. for the full year (compared to 1,989 t.kr. last year – Q4 included) Operating profit (EBIT): -14,967 t.kr. → large negative result, but improved compared to the previous year Net profit/loss for the year: -10,904 t.kr. → continued loss, but reduced loss compared to last year Earnings per share: -0.60 DKK (compared to -0.04 in the quarter) Cash balance at year-end: 8,591 t.kr. Solvency (equity ratio): 91 % – very high solidity No dividend is proposed for 2025. 🚀 Business and development highlights Positive top-line results from the concluding pediatric clinical Study 0202 for CT001 – supports safety and efficacy, and enables initiation of the EU regulatory approval process. Positive Notified Body opinion under EU MDR for CT001 – cleared approval status for the device part. PUMA application (EU's pediatric authorization) for CT001 has been submitted and validated by EMA. Progress in USA: Deepened collaborations and completed technology transfer with STAQ Pharma to support future hospital supply. Strengthened financial position through a directed share issue of approx. DKK 15 mio. Management reinforcement: Martin Juhl joins as CSO. 🧩 Summary / Conclusion Cessatech ended 2025 with increased revenue and reduced loss compared to the previous year. There are significant clinical and regulatory advancements, especially concerning the product CT001 – which is the core product for acute pain management in children. The company is moving closer to the EU approval process and USA activities, but is still at a loss. No dividend is still proposed, and the focus is on strengthening the pipeline and commercialization. In short: The economy is gradually improving, and clinical/regulatory progress is moving Cessatech closer to the potential for commercialization of their main product.·13 t sittenThe most important thing must be that they, as they have said they can, have gone into economic hibernation. They have therefore only burned through 1,8 mio dkk since the last financial report, which must be said to be extremely impressive. So the cash of 8,5 mio dkk and the loan facility of 10 mio dkk will go a long way :)
- ·1 päivä sittenThere is an earnings report tomorrow. Does anyone have any insight/input they want to share? Do we believe in a positive? :-)
- ·20.2.On October 31, 2025, one could read under News that Casatech was approaching the time for the launch of their product in the USA, it has now been almost 4 months since, I know that things take time, but surely there will soon be some kind of announcement about the launch, or could it be that the launch will happen in connection with the event in Denver this March (2026)?·21.2.I understand that we are waiting for some technical results that need to be in place before the launch in the USA. I imagine they are waiting for stability results that can provide commercially meaningful durability, without actually knowing it. I agree that it would be elegant if the launch was in place in connection with the Denver congress. However, I also don't know if it's Cessatech participating alone or if Ventis also participates, which seems more relevant. I also don't think it's clear if Ventis starts by launching products in their dental division or for pediatric pain treatment? Or both simultaneously?? It sometimes seems a bit like Cessatech is a kind of sub-division of the Secret Service. But I hope they have something cool to tell next time they announce something. And preferably soon.
- ·20.2.Why are people in such a hurry to sell out🤣·20.2.There are only a meager 21607 units traded today. Apparently no one is in a hurry. Furthermore, up by 5% right now so not exactly a sign of a sell-off.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 50 | NON | AVA | ||
| 3 | NON | NON | ||
| 298 | NON | NON | ||
| 2 | NON | NON | ||
| 1 000 | NON | AVA |
Ylin
18,96VWAP
Alin
17,62VaihtoMäärä
0,9 49 877
VWAP
Ylin
18,96Alin
17,62VaihtoMäärä
0,9 49 877
Välittäjätilasto
Dataa ei löytynyt